A review of oxaliplatin and its clinical use in colorectal cancer
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is one of the leading causes of death from malignant diseases in the Western world. Worldwide, approximately 50% of patients who present with colorectal cancer will develop metastatic disease and eventually die from this malignancy. Recently, significant advances have been made in the medical treatment of advanced colorectal cancer with the introduction of novel cytotoxic drugs, such as irinotecan and oxaliplatin. Based on the results of recent Phase III trials, combination regimens of infusional 5-fluorouracil/leucovorin and oxaliplatin (FOLFOX) have emerged as a new standard of care in the palliative and adjuvant treatment of colorectal cancer. The addition of biological agents targeting angiogenesis or oncogenes such as epidermal growth factor receptor (EGFR) to FOLFOX will conceivably further enhance the activity of treatment regimens. Making use of all available active therapeutic options in the course of disease has significantly improved median overall survival of metastatic colorectal cancer into a chronic disease, with implications for treatment strategies and pharmacoeconomic considerations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 4×
“2 Oxaliplatin-based regimens as first-line therapy In three Phase III trials, the combination of several methods for the delivery of infusional 5-FU/LV plus oxaliplatin (FOLFOX or FUFOX) were compared with 5-FU/LV as first-line therapy in advanced CRC [5,8,10].”
BackgroundMethodInfluentialDouillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 2×
“(2004) 5(10) plus irinotecan) emerging as interim standard of care in 2000 (Table 1) [5-8,10,48].”
BackgroundTournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070 · cited 1×
“A recent analysis highlights the impact of patients’ access to all three active cytotoxic drugs in the course of their treatment on OS [55].”
BackgroundSelf-citationPalliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis
Colorectal Cancer Collaborative Group (2000) · BMJ · doi:10.1136/bmj.321.7260.531 · Cited by 662
Cited by
Block copolymer micelles in nanomedicine applications
Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309
Progress of drug-loaded polymeric micelles into clinical studies
Cabral, H., & Kataoka, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.042 · Cited by 837
A review on oxaliplatin-induced peripheral nerve damage
Argyriou, A. A., Polychronopoulos, P., Iconomou, G., Chroni, E., & Kalofonos, H. P. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.01.003 · Cited by 330
Interventions for preventing neuropathy caused by cisplatin and related compounds
Albers, J. W., Chaudhry, V., Cavaletti, G., & Donehower, R. C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005228.pub4 · Cited by 298
Shi, Y., Lammers, T., Storm, G., & Hennink, W. E. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201600160 · Cited by 174
Metadata
- Authors
- Grothey, A., & Goldberg, R. M.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2004-10
- Volume
- 5
- Issue
- 10
- Pages
- 2159-2170
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2169358424
- Cited by
- 114
- References
- 6
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review of oxaliplatin and its clinical use in colorectal cancer. https://app.cochat.ai/papers/10.1517/14656566.5.10.2159
- The paper
- Grothey, A., & Goldberg, R. M. (2004). A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.5.10.2159
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.